Kinase News and Research

RSS

Researchers identify a protein that could potentially stop cancer

Scientists know that most cancer cells use glucose to fuel their uncontrolled growth and now an international team of researchers has identified a protein which if switched off could stop the disease in its tracks.

22 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

Researchers identify triple mechanism that prevents onset of chromosomal instability

Universitat Autònoma de Barcelona researchers have identified for the first time the triple mechanism that stops chromosome separation in response to situations that compromise the integrity of the genetic information. The loss of this response capacity is characteristic of cancerous cells.

18 Sep 2015

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

In metastatic renal cell carcinoma patients, there is no significant correlation between adverse event profiles of first- and second-line tyrosine kinase inhibitors, suggests a Japanese study.

17 Sep 2015

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Researchers in Japan have shown that several different classes of antidepressants increase early growth responses in astrocytes, star-shaped glial cells, which could help develop new treatments.

16 Sep 2015

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

Avillion LLP, a co-developer of late-stage pharmaceutical assets, announces the completion of enrolment in a global Phase III clinical trial called "BFORE," which is designed to assess the effectiveness and safety of BOSULIF (bosutinib) as a first-line treatment for patients with chronic phase Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML).

15 Sep 2015

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

A class of therapeutic drugs known as protein kinase inhibitors has in the past decade become a powerful weapon in the fight against various life-threatening diseases, including certain types of leukemia, lung cancer, kidney cancer and squamous cell cancer of the head and neck.

11 Sep 2015

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Mirati Therapeutics, Inc., an oncology company focusing on genetic and epigenetic drivers of cancer, today announced it will present data on its tyrosine kinase inhibitor, MGCD516, at the ESMO 2015 European Cancer Congress being held in Vienna, Austria from September 25-29, 2015.

11 Sep 2015

Researchers now have a way to study special proteins linked to different diseases, cancer

Researchers from Northwestern University and Yale University have developed a user-friendly technology to help scientists understand how proteins work and fix them when they are broken. Such knowledge could pave the way for new drugs for a myriad of diseases, including cancer.

11 Sep 2015

Inhibition of Tyk2 enzyme promotes anti-cancer activity

Tyrosine kinase 2 (Tyk2) is an enzyme involved in intracellular signalling and has an important role in activating the immune system.

11 Sep 2015

EMBL researchers use mass spectrometry data to analyze effects of cancer drugs

Researchers at EMBL's European Bioinformatics Institute (EMBL-EBI) have developed a new method for studying the targets and effects of cancer drugs using data from discovery mass spectrometry (MS) experiments.

11 Sep 2015

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Two members of the vascular endothelial growth factor family are highly specific and moderately sensitive for the presence of pulmonary hypertension, report researchers.

10 Sep 2015

Scientists identify new drug target to treat heart arrhythmias

Scientists at The Ohio State University Davis Heart and Lung Research Institute have identified a new target they hope will help make the next drug discovery for patients suffering from heart arrhythmias happen sooner.

9 Sep 2015

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

Rigel Pharmaceuticals, Inc. announced that the U.S. Food and Drug Administration has granted Orphan Drug designation to Fostamatinib, Rigel's oral spleen tyrosine kinase (SYK) inhibitor which is currently in Phase 3 clinical studies in patients with chronic immune thrombocytopenic purpura (ITP).

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Researchers provide new insights into biology of aging, age-related diseases

The scientific team of a new biotech company Gero in collaboration with one of the leading academics in the field of aging Prof. Robert J. Shmookler Reis (current world record holder in life extension for model animals - 10 fold for nematodes) has recently brought new insights into biology of aging and age-related diseases, primarily, around the stability and stress resistance of certain gene regulatory networks.

28 Aug 2015

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

Researchers have discovered how a common mutation in a high-risk leukemia subtype drives the cancer's aggressiveness and have identified drugs that may work with existing precision medicines to improve survival. St. Jude Children's Research Hospital scientists led the study, which was published online today in the journal Cancer Cell.

28 Aug 2015

FSU investigator solves cell division mystery

In the second part of his lab's recent one-two punch, Florida State University researcher Daniel Kaplan said he has solved a cell division mystery in a way that will intrigue the makers of cancer-fighting drugs.

25 Aug 2015

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

Afatinib (trade name: Giotrif) has been approved since September 2013 for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGF receptor mutations who have not been treated with an EGF receptor tyrosine-kinase inhibitor (EGFR TKI).

21 Aug 2015

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

caprotec bioanalytics GmbH announced today that the United States Patent Office has issued patent No. US9,034,789 covering its revolutionary Capture Compound Mass Spectrometry (CCMS) technology.

20 Aug 2015

Kinase News and Research

Researchers identify a protein that could potentially stop cancer

BGB324 shows enhanced tumour clearance in mouse carcinoma models

Researchers identify triple mechanism that prevents onset of chromosomal instability

First-line TKI adverse event profile has no bearing on second-line RCC treatment choice

New findings on amitriptyline drug could help develop antidepressants with novel mechanisms

Avillion enrolls patients in BFORE Phase III trial to treat chronic myelogenous leukemia

New technique could improve selectivity of cancer drugs, decrease unwanted side effects in future

Mirati to present data on tyrosine kinase inhibitor at ESMO 2015 European Cancer Congress

Researchers now have a way to study special proteins linked to different diseases, cancer

Inhibition of Tyk2 enzyme promotes anti-cancer activity

EMBL researchers use mass spectrometry data to analyze effects of cancer drugs

VEGF family biomarkers ‘promising’ tools for pulmonary hypertension diagnosis

Scientists identify new drug target to treat heart arrhythmias

FDA grants Orphan Drug designation to Rigel's Fostamatinib for treatment of patients with ITP

AstraZeneca presents lung cancer research data at WCLC 2015

Researchers provide new insights into biology of aging, age-related diseases

Researchers identify drugs that may enhance ability of TKI dasatinib to kill human cancer cells

FSU investigator solves cell division mystery

IQWiG dossier assessment finds added benefit of afatinib in patients with certain mutations

caprotec bioanalytics issued U.S. patent for CCMS proteome analysis technology

Measuring Drug-Target Residence Times with Biochemical Assays eBook

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News